• About
  • Tests
  • Resources
  • News
  • Contact
  • Download Test Order Form
Order Tests Now
Annual Association For Molecular Pathology Presentation

Annual Association For Molecular Pathology Presentation

by pesbm-sam | Feb 14, 2024 | Healthcare

Precision Epigenomics Inc. presents a bioinformatics study…
Digestive Disease Week Presentation

Digestive Disease Week Presentation

by pesbm-sam | Feb 10, 2024 | Healthcare

Precision Epigenomics Inc. presents a pilot study of the performance of EPISEEK™ for hepatocellular carcinoma at the Digestive Disease Week Annual Meeting 2023 in Chicago
American Thoracic Society Presentation

American Thoracic Society Presentation

by pesbm-sam | Feb 8, 2024 | Healthcare

Precision Epigenomics Inc. presents results of the performance of the EPISEEK-MPE™ test at the annual American Thoracic Society meeting 2023 in Washington, DC
National Human Genome Research Training Grant

National Human Genome Research Training Grant

by pesbm-sam | Jan 20, 2024 | Industry

Precision Epigenomics Inc. and Arizona State University collaborators are awarded a training grant by National Human Genome Research Institute to train students in bioinformatics through the Training in Genomics Research program
Molecular Test for Indeterminate Melanoma Lesions Pilot Program

Molecular Test for Indeterminate Melanoma Lesions Pilot Program

by pesbm-sam | Aug 14, 2023 | Diagnosis

Precision Epigenomics Inc. and University of Arizona collaborators awarded a pilot project to develop a new molecular test for indeterminate melanoma lesions
« Older Entries

Recent Posts

  • Precision Epigenomics Highlighted by Tucson News 13 for Multi-Cancer Early Detection Blood Test Development
  • Precision Epigenomics Shares Abstracts Showing Performance of Assays for Melanoma and Brain Cancer Detection 
  • Precision Epigenomics Announces Closing of $1.5M Series A1 Funding 
  • Precision Epigenomics Receives $2M Award from National Institutes of Health
  • 2024 Flinn Foundation Bioscience Entrepreneurship Program Partner

Recent Comments

No comments to show.
The EPISEEK™ test is recommended for use in adults with an elevated risk for cancer, such as those aged 45 or older. The EPISEEK™ test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. EPISEEK™ is intended to detect cancer signals. Use of EPISEEK™ is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of Cancer Signal Not Detected does not completely rule out cancer. A test result of Abnormal Methylation Signal Detected requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm or exclude the presence of cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present (i.e. EPISEEK™ false positive) or confirmatory testing was insufficient to detect a very early cancer (follow up testing false negative). False positive (abnormal methylation signal detected when cancer is not present) and false negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow

Quick Links

Home
About
Tests
Resources
News
Contact

Other Pages

Privacy Policy
Terms & Conditions
FCOI

Contact Info



630 N Alvernon Way
Ste 280B
Tucson, AZ 85711



520.372.7522



520.777.7367

  • Follow
  • Follow
  • Follow
  • Follow
  • Follow